TANGRAM THERAPEUTICS
Live / Registered — Registered (as of 24 Feb 2026)
What this means for you
Registered since 24 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99163593
- Registration number
- 8148819
- Mark type
- Stylized text
- Filed
- 30 Apr 2025
- Published for opposition
- 06 Jan 2026
- Registered
- 24 Feb 2026
- Attorney of record
- Anna King
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.
- Class 042 — Scientific and technological services: Scientific research and development; pharmaceutical research and development services; drug discovery services; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; design and development of computer-simulated models; Software as a Service (SaaS) services featuring computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; software as a service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.
Owner
- E-THERAPEUTICS PLC, LONDON, GB
- E-THERAPEUTICS PLC, LONDON, GB
- E-THERAPEUTICS PLC, LONDON, GB
Prosecution history
- 24 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 06 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 Jan 2026 — PUBLISHED FOR OPPOSITION
- 31 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 20 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 20 Sept 2025 — NON-FINAL ACTION E-MAILED
- 20 Sept 2025 — NON-FINAL ACTION WRITTEN
- 19 Sept 2025 — ASSIGNED TO EXAMINER
- 09 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Apr 2025 — APPLICATION FILING RECEIPT MAILED